ICER draft report: Aimmune's peanut allergy therapy cost effective, DBV's falls short

ICER thinks Aimmune's peanut allergy therapy AR101 could be cost effective but found that DBV’s Viaskin Peanut exceeded standard cost-effectiveness ratios, according to a draft evidence report published Tuesday.

The institute said both therapies may provide some benefit for patients relative

Read the full 408 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE